Simcere Approved to Start China Trial of Gout Treatment
December 02, 2020 at 05:18 AM EST
Simcere Pharma of Nanjing was approved to start China trials of a novel treatment for gout. URC102 is a selective inhibitor of uric acid transporter (URAT-1). One year ago, Simcere entered a $70 million agreement for China rights to URC102 from JW Pharma of Korea . In a Korea Phase IIa trial, the candidate was effective and well-tolerated. Present therapies for gout have side effects that limit their usefulness, the companies said. More details.... Stock Symbols: (HK: 2096) (KRX: 001060) Share this with colleagues: // //
